Lilly’s cancer business loses its chief just as it’s leaning on oncology for growth

Eli Lilly is leaning on oncology as a key pillar for growth going forward, but with news that its president of the business, Sue Mahony, is retiring, the drugmaker will need to find new leadershi…
Read the full story: FiercePharma: Pharma